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Viral infections
Patients with inflammatory rheumatic conditions 
have an increased risk of infection, including viral 
infections.[1] Rheumatological manifestations, such 
as arthritis, are also relatively common occurrences 
with viral infections.
Hepatitis B
The prevalence of hepatitis B virus (HBV) in rheumatic patients has 
recently been reported at ~3% in a large cross-sectional study on 
comorbidities, which included almost 4  000 rheumatoid arthritis 
(RA) patients at 17 centres worldwide.[2] The prevalence differed 
according to geographical area – more infections in Asia and fewer 
in Europe and the USA. However, it demonstrates this common 
problem in daily rheumatological practice owing to the risk of 
hepatitis B reactivation through immunosuppressive therapy.
According to the American College of Rheumatology (ACR) 
guidelines and the views of experts, RA patients should be screened 
for HBV before initiation of methotrexate, leflunomide and biologic 
therapies.[3] Patients with chronic hepatitis B should receive treatment 
with oral antivirals before starting therapy. Those with significant 
liver damage should, however, not receive these immunosuppressive 
drugs.
There are no guidelines with regard to the use of synthetic 
disease-modifying anti-rheumatic drugs (sDMARDs) and biologics 
in patients with a history of hepatitis B infection (hepatitis B core 
antibody positive). A significant population of those who were 
exposed to HBV, have cleared the virus. Depending on the prevalence 
of chronic HBV infection, the prevalence of past HBV infection varies 
between 5% and 80% worldwide. In the literature on haematology 
(lymphomas), rituximab-containing chemotherapy regimens lead 
to reactivation in 3 - 25% of patients with past HBV infection.[4] As 
data are limited, it is not clear if pre-emptive antiviral prophylaxis is 
needed in a rheumatological setting, but recently a large prospective 
study in >1 200 RA patients demonstrated a risk of reactivation 
in cases of previous HBV infection (15%) treated with biologics.[5] 
The majority were treated with anti-tumour necrosis factor (anti-
TNF), but rituximab and other biologics were also used. It was 
reassuring that there were no observed cases of HBV reactivation 
during biologic treatment. This confirms the results of previous 
studies that the risk of HBV reactivation in patients with rheumatic 
diseases and a history of HBV infection treated with anti-TNF and 
rituximab is very low.[6] However, more studies should be done to 
assess the need for pre-emptive antiviral prophylaxis in patients 
with past HBV infection. In practice, regular monitoring for viral 
reactivation during therapy, particularly in patients lacking evidence 
of immunity (HBsAb negative), is necessary. If the transaminase 
levels are increased, HBV DNA should be checked and antiviral 
therapy initiated if reactivation occurs. 
Hepatitis C
Hepatitis C virus (HCV) infection is a major global health problem, 
with a prevalence of 2.8%. Universal screening for individuals between 
the ages of 45 and 65 years is recommended by the US Centers for 
Disease Control and Prevention (CDC).[7] HCV can be associated 
with rheumatic syndromes, such as the potentially serious rheumatic 
complication of HCV-associated cryoglobulinaemic vasculitis (CV). 
To treat HCV, interferon alpha (IFNα)-based regimens can achieve 
viral clearance in about 50% of patients, but it has many side-effects 
(e.g. cytopenias, depression, flu-like symptoms) and renal impairment 
is a contraindication. New oral direct-acting antivirals (DAAs) are 
being introduced into clinical practice. A prospective cohort study 
on treatment with a combination of first-generation DAAs with 
PegIFNα and ribavirin in 30 patients with severe refractory CV, who 
were not responding to standard treatment with antiviral therapy, was 
published recently.[8] After 1 year of treatment, 67% of these patients 
showed a clinical response, with total clearance of the virus. However, 
there were many side-effects, such as cytopenias and infections. 
Fortunately, the newer DAAs, which target specific proteins such 
as non-structural protein 3b/4A/5A, will it is hoped signal the end 
of interferon use in HCV patients in the future.[9,10] These new drugs 
could possibly cure the disease in >90% of patients, with fewer 
side-effects. They are extremely expensive and only administered to 
patients with the highest risk of complications, such as those with 
CV with end-organ manifestations.[11] Despite the high cost, they are 
considered to be cost-effective.[12] Data on these new drugs in patients 
with rheumatic diseases are confined to a few case reports, but several 
trials are currently underway.
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Data on the use of biologics in patients with hepatitis C infections 
are scarce. Biologics are contraindicated in cases of acute or chronic 
HCV infection with significant liver damage, as progression of 
HCV has been described in such patients who receive biologics. In 
RA patients with chronic HCV infection without significant liver 
damage, rituximab and anti-TNF (the ACR suggests etanercept 
as the preferred anti-TNF) may be used, but monitoring of serum 
transaminases is advised. 
Herpes zoster 
Reactivation of the latent varicella zoster virus causes herpes zoster 
(HZ), a painful vesicular skin rash that could be complicated 
by chronic pain and post-herpetic neuralgia. In patients with 
rheumatic disease, the incidence of HZ is almost 12 times higher in RA, 
20 times higher in systemic lupus erythematosus (SLE) and 45 times 
higher in Wegener’s granulomatosus.[13] This increased risk of HZ 
is caused by the underlying disease, especially in those receiving 
immunosuppressive therapy.[14] A recent review showed that there 
was some increased risk with the use of biologics (anti-TNF) and 
sDMARDs,[15] but that high-dose corticosteroids and cyclophosphamide 
led to the highest increase in risk.
HIV 
HIV can cause several rheumatological manifestations, including an 
inflammatory polyarthritis mimicking RA. Therefore, an HIV test 
may be useful in patients presenting with inflammatory arthritis. HIV 
can also result in several challenges in the management of patients 
with rheumatic diseases, who are also HIV-positive, especially if not 
on antiretroviral treatment. Data on the safety of immunosuppressive 
drugs in HIV-positive patients are limited, but there have been 
reports on the use of sDMARDs and TNF-α inhibitors to treat RA 
or other inflammatory conditions in HIV infection.[16,17] In general, 
these reports suggest that DMARDs such as methotrexate and anti-
TNF are tolerated well by HIV-positive patients, provided that the 
patients are on an effective antiretroviral regimen before the start of 
therapy.
Vaccinations
According to the latest recommendations by the CDC, immuno-
compromised patients such as those with rheumatic diseases 
should receive killed (pneumococcal, annual intramuscular 
influenza and hepatitis B) and recombinant (human papillomavirus 
(HPV)) vaccines before starting an sDMARD or a biologic.[18] It 
also recommends that, if not previously done, vaccination with 
pneumococcal, intramuscular influenza, HBV and HPV vaccines 
should be done in patients already taking an sDMARD or a biologic. 
All vaccines should be given based on age and risk, and physicians 
should refer to vaccine instructions and CDC recommendations for 
details about dosing and timing. Importantly, both the pneumococcal 
polysaccharide vaccine (PPSV23) and the 13-valent conjugate 
pneumococcal vaccine (PCV13) should be given. In non-immunised 
patients, one should start with the PCV13, then wait for 2 months, 
and thereafter administer the PPSV23 vaccine. In patients <65 years 
of age, a repeat dose of the PPSV23 should be given after 5 years. Live 
virus vaccines (such as the live attenuated influenza vaccine; measles, 
mumps, rubella) should not be administered to immunosuppressed 
patients with rheumatic diseases. 
The COMORA study showed how often patients with rheumatic 
diseases were being vaccinated.[2,19] This study was performed at 
17 centres worldwide, where 25% of RA patients had received an 
influenza vaccination in the past year, 17% a pneumococcal vacci-
nation in the past 5 years, and only 10% both vaccinations. It is 
not known how often South African (SA) patients with rheumatic 
diseases are vaccinated, but this shows that clinicians, especially 
rheumatologists, must do more to ensure adequate vaccination in 
these patients. 
Efficacy and safety of the HZ vaccine
In immunocompetent individuals the risk of HZ can be reduced by 50 - 
70% with a live attenuated vaccine.[20] According to the ACR guidelines, 
the live HZ vaccine may be given to all patients with rheumatic diseases 
before starting immunosuppressive therapy.[3] Once on such therapy, 
patients may receive the vaccine if treated with sDMARDs (mono- 
or combination therapy), but it is contraindicated in those receiving 
biologics or high-dose steroids (prednisone >20  mg/day) owing to a 
concern of developing a varicella infection from the vaccine virus strain. 
Recently a study on the association between HZ vaccination and 
the risk of HZ infection in patients with immune-mediated diseases 
such as RA, psoriatic arthritis and ankylosing spondylitis was 
published.[21] Of the 465  000 patients, <5% were vaccinated against 
HZ. The vaccine, however, showed a similar efficacy in healthy 
individuals, with a decreased risk of HZ (adjusted hazard ratio (HR) 
0.61) and an 80% decrease in post-herpetic neuralgia. Interestingly, 
in the 633 patients who were treated with biologics (87% on anti-
TNF), there were no cases of varicella or HZ. The ACR published an 
update suggesting that it may be reasonable to discontinue a biologic 
for a period, administer the HZ vaccine and then resume the biologic 
after 30 days. 
Tuberculosis 
The 2012 ACR guidelines recommend screening for latent tuber-
culosis (TB) infection (LTBI) in all patients with rheumatic diseases 
being considered for biologic therapy, regardless of the presence of 
risk factors.[3] Doctors should assess the patient’s medical history to 
identify other risk factors (such as smoking and corticosteroid use) for 
TB and perform the tuberculin skin test (TST) or interferon-gamma-
release assays (IGRAs) initially in all patients starting biologic agents. 
Patients should have a chest radiograph and, if suggestive of active 
TB, a sputum examination should be done to test for the presence of 
active TB. In a high-prevalence TB setting such as SA, these screening 
tests are not always reliable and there is little consensus on the most 
appropriate test,[22] but a TST and/or an IGRA (if deemed appropriate 
by the clinician) may be performed. If both tests are used, they should 
be done at the same time, as TST could boost IGRA responses, which 
may confound the interpretation of the results. 
Chemoprophylactic drugs for LTBI may be either isoniazid (INH) 
for 9 months or rifampicin combined with INH for 3 months. 
Treatment with biologic agents can be initiated or resumed after 1 month 
of LTBI treatment and after completion of the treatment of active TB. 
Some experts and studies suggest that non-TNF biologic therapies, 
such as rituximab and abatacept, are safer and better choices as first-
line biologics in patients in high-burden settings.[23] 
It remains uncertain how to manage RA patients with a negative 
initial screening for TST or IGRA on chronic biologic therapy. 
In low-prevalence TB settings patients may not need further 
evaluation in the absence of risk factors and/or clinical suspicion 
for TB. However, patients may have false-negative TST or IGRA 
results owing to immunosuppression. Therefore, a negative TST 
or IGRA does not exclude the possibility that a patient has LTBI. 
An updated consensus statement by the ACR recommends that 
repeat screening should be considered in areas of high TB risk 
populations or in the case of potential TB exposure. Recent 
studies, however, have shown that TB conversions may occur 
during anti-TNF therapy in ~10% of RA patients.[24] It is unclear 
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if these conversions always represent ‘true conversions’. More data 
are needed to make recommendations regarding rescreening in 
the absence of definite TB exposure.
Serious infections in RA
It is not well understood why patients with RA have an increased 
prevalence of other serious infections, particularly pulmonary, 
urinary tract, skin, and joint infections. Factors that may contribute 
include immunosuppression by the disease, treatment of the disease, 
presence of inflammatory lung disease, or factors associated with 
disability and immobility. Compared with the increased risk of 
infection associated with the use of corticosteroids and biologics, the 
sDMARDs do not appear to be associated with such a risk.
Biologics have been used in RA for almost 15 years and rheuma-
tologists have gained much experience with these drugs. A large number 
of randomised controlled trials have been published on their efficacy 
and safety, and data exist from national registries worldwide. An 
important question that often arises with regard to a patient taking 
these drugs is: ‘What is the risk of a serious infection when on 
biologic therapy compared with being on sDMARDs?’ 
A number of meta-analyses have assessed this risk.[25-27] Recently, 
the largest meta-analysis to date (>42 000 patients) assessed the 
rate of serious infection in RA.[28] The authors found that if the 
rate of serious infection on standard doses of biologic therapy 
(with or without sDMARDs) is compared with that of sDMARD 
mono therapy, the risk is increased by 30% (odds ratio 1.31). It is 
important to understand what this means in absolute numbers. The 
absolute annual risk for serious infections when using sDMARD 
monotherapy is 2%. Therefore, 2% of the RA population on 
sDMARDs experience a serious infection every year. The risk 
was increased by 30% when using biologic therapy, resulting in 
an absolute risk of 2.6%. The absolute increase in the number of 
serious infections compared with traditional DMARDs was 6/1 000 
patients per year for standard-dose biologic therapy with or without 
traditional DMARDs. One would therefore have to treat 1 000 RA 
patients with biologic therapy to cause 6 more serious infections 
compared with traditional DMARDs. 
Serious infections in SLE
The risk of serious infections in cases of SLE was reviewed recently.[29] 
In SLE, 20 - 30% of deaths are caused by infections. In a US study, the 
rate of serious infections in SLE was ~10.8/100 patient-years, which 
is approximately 5 times higher than in RA patients.[30] In lupus 
nephritis (LN) this risk was almost 12 times higher than in RA 
patients, i.e. 23.9/100 patient-years. Men and black patients with 
SLE were found to have an increased risk of serious infection. In 
this study, traditional immunosuppressive therapy in SLE, such 
as azathioprine, mycophenolate mofetil and cyclophosphamide, 
showed a 10% increased risk (HR 1.11), but not in the LN group (HR 
0.92). With the use of corticosteroids there was an increased risk of 
>50% (HR 1.51) in SLE and almost 25% in LN patients (HR 1.23). 
Interestingly, the rate of serious infections was decreased by almost 
30% in SLE and 20% in LN when using chloroquine. The most 
common serious infections in SLE are bacterial, such as pneumonia, 
urinary tract infection, opportunistic infection, sepsis and skin 
infections.[31] These studies confirm the importance of limiting the 
dose of corticosteroids in SLE patients.
Conclusion
Patients with rheumatic diseases have an increased risk of infections 
owing to their condition and immunosuppressive therapies. This 
article highlights the latest research findings with regard to the 
most important infections encountered in the daily management of 
patients with rheumatic diseases. This knowledge can be used when 
balancing the potential harm and the clinically important benefits of 
sDMARDs and biologics and will assist patients and their physicians 
to make evidence-based decisions. 
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